Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics.

Clay-Gilmour AI, Kumar S, Rajkumar SV, Rishi A, Kyle RA, Katzmann JA, Murray DL, Norman AD, Greenberg AJ, Larson DR, O'Byrne MM, Slager SL, Vachon CM.

Leukemia. 2019 Feb;33(2):499-507. doi: 10.1038/s41375-018-0246-2. Epub 2018 Sep 10.

2.

Restricted IgG-Kappa and Free Alpha-Heavy-Chain Bands in an Asymptomatic 62-Year-Old Man.

Yu M, Bruns DE, Katzmann JA, Silverman LM, Murray DL.

Clin Chem. 2018 Feb;64(2):265-268. doi: 10.1373/clinchem.2016.269050. No abstract available.

3.

Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey.

Landgren O, Graubard BI, Kumar S, Kyle RA, Katzmann JA, Murata K, Costello R, Dispenzieri A, Caporaso N, Mailankody S, Korde N, Hultcrantz M, Therneau TM, Larson DR, Cerhan JR, Rajkumar SV.

Blood Cancer J. 2017 Oct 20;7(10):e618. doi: 10.1038/bcj.2017.97.

4.

Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry.

Mills JR, Kohlhagen MC, Dasari S, Vanderboom PM, Kyle RA, Katzmann JA, Willrich MA, Barnidge DR, Dispenzieri A, Murray DL.

Clin Chem. 2016 Oct;62(10):1334-44. doi: 10.1373/clinchem.2015.253740. Epub 2016 Aug 18.

5.

Screening Method for M-Proteins in Serum Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry.

Kohlhagen MC, Barnidge DR, Mills JR, Stoner J, Gurtner KM, Liptac AM, Lofgren DI, Vanderboom PM, Dispenzieri A, Katzmann JA, Willrich MA, Snyder MR, Murray DL.

Clin Chem. 2016 Oct;62(10):1345-52. doi: 10.1373/clinchem.2015.253781. Epub 2016 Aug 11.

6.

Monitoring free light chains in serum using mass spectrometry.

Barnidge DR, Dispenzieri A, Merlini G, Katzmann JA, Murray DL.

Clin Chem Lab Med. 2016 Jun 1;54(6):1073-83. doi: 10.1515/cclm-2015-0917.

PMID:
26845720
7.

Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation.

Willrich MA, Ladwig PM, Andreguetto BD, Barnidge DR, Murray DL, Katzmann JA, Snyder MR.

Clin Chem Lab Med. 2016 Jun 1;54(6):1085-93. doi: 10.1515/cclm-2015-1023.

PMID:
26812875
8.

Monitoring oligoclonal immunoglobulins in cerebral spinal fluid using microLC-ESI-Q-TOF mass spectrometry.

Barnidge DR, Kohlhagen MC, Zheng S, Willrich MA, Katzmann JA, Pittock SJ, Murray DL.

J Neuroimmunol. 2015 Nov 15;288:123-6. doi: 10.1016/j.jneuroim.2015.09.011.

PMID:
26531705
9.

Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias.

Willrich MA, Katzmann JA.

Clin Chem Lab Med. 2016 Jun 1;54(6):907-19. doi: 10.1515/cclm-2015-0580. Review.

10.

Quantitation of circulating wild-type alpha-1-antitrypsin in heterozygous carriers of the S and Z deficiency alleles.

Donato LJ, Karras RM, Katzmann JA, Murray DL, Snyder MR.

Respir Res. 2015 Aug 5;16:96. doi: 10.1186/s12931-015-0256-9.

11.

Elevation of serum immunoglobulin free light chains during the preclinical period of rheumatoid arthritis.

Deng X, Crowson CS, Rajkumar SV, Dispenzieri A, Larson DR, Therneau TM, Matteson EL, Kyle RA, Katzmann JA, Gabriel SE, Davis JM 3rd.

J Rheumatol. 2015 Feb;42(2):181-7. doi: 10.3899/jrheum.140543. Epub 2015 Jan 15.

12.

Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays.

Katzmann JA, Willrich MA, Kohlhagen MC, Kyle RA, Murray DL, Snyder MR, Rajkumar SV, Dispenzieri A.

Clin Chem. 2015 Feb;61(2):360-7. doi: 10.1373/clinchem.2014.231985. Epub 2014 Dec 1.

13.

Commentary.

Katzmann JA.

Clin Chem. 2014 Nov;60(11):1378. doi: 10.1373/clinchem.2014.224873. No abstract available.

14.

Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma.

Witzig TE, Maurer MJ, Habermann TM, Link BK, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Markovic SN, Johnston PB, Lin Y, Thompson C, Gupta M, Katzmann JA, Cerhan JR.

Am J Hematol. 2014 Dec;89(12):1116-20. doi: 10.1002/ajh.23839. Epub 2014 Sep 26.

15.

Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry.

Barnidge DR, Dasari S, Ramirez-Alvarado M, Fontan A, Willrich MA, Tschumper RC, Jelinek DF, Snyder MR, Dispenzieri A, Katzmann JA, Murray DL.

J Proteome Res. 2014 Nov 7;13(11):5198-205. doi: 10.1021/pr5005967. Epub 2014 Aug 26.

PMID:
25134970
16.

Detecting monoclonal light chains in urine: microLC-ESI-Q-TOF mass spectrometry compared to immunofixation electrophoresis.

Botz CM, Barnidge DR, Murray DL, Katzmann JA.

Br J Haematol. 2014 Nov;167(3):437-8. doi: 10.1111/bjh.13003. Epub 2014 Jul 7. No abstract available.

PMID:
25039602
17.

Quantification of serum IgG subclasses by use of subclass-specific tryptic peptides and liquid chromatography--tandem mass spectrometry.

Ladwig PM, Barnidge DR, Snyder MR, Katzmann JA, Murray DL.

Clin Chem. 2014 Aug;60(8):1080-8. doi: 10.1373/clinchem.2014.222208. Epub 2014 May 5.

18.

Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS.

Barnidge DR, Tschumper RC, Theis JD, Snyder MR, Jelinek DF, Katzmann JA, Dispenzieri A, Murray DL.

J Proteome Res. 2014 Apr 4;13(4):1905-10. doi: 10.1021/pr5000544. Epub 2014 Mar 5.

PMID:
24552626
19.

Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy.

Barnidge DR, Dasari S, Botz CM, Murray DH, Snyder MR, Katzmann JA, Dispenzieri A, Murray DL.

J Proteome Res. 2014 Mar 7;13(3):1419-27. doi: 10.1021/pr400985k. Epub 2014 Feb 11.

PMID:
24467232
20.

Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey.

Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R, Kumar SK, Dispenzieri A, Greenberg AJ, Therneau TM, Melton LJ 3rd, Caporaso N, Korde N, Roschewski M, Costello R, McQuillan GM, Rajkumar SV.

Leukemia. 2014 Jul;28(7):1537-42. doi: 10.1038/leu.2014.34. Epub 2014 Jan 20.

21.

Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma.

Witzig TE, Maurer MJ, Stenson MJ, Allmer C, Macon W, Link B, Katzmann JA, Gupta M.

Am J Hematol. 2014 Apr;89(4):417-22. doi: 10.1002/ajh.23658. Epub 2014 Feb 10.

22.

A window into immunoglobulin quantitation and plasma cell disease: antigen epitopes defined by the junction of immunoglobulin heavy and light chains.

Katzmann JA, Rajkumar SV.

Leukemia. 2013 Jan;27(1):1-2. doi: 10.1038/leu.2012.201. No abstract available.

PMID:
23299499
23.

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.

Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV.

Leukemia. 2013 Apr;27(4):941-6. doi: 10.1038/leu.2012.296. Epub 2012 Oct 16.

24.

Laboratory persistence and clinical progression of small monoclonal abnormalities.

Murray DL, Seningen JL, Dispenzieri A, Snyder MR, Kyle RA, Rajkumar SV, Katzmann JA.

Am J Clin Pathol. 2012 Oct;138(4):609-13.

25.

Reference and interpretive ranges for α(1)-antitrypsin quantitation by phenotype in adult and pediatric populations.

Donato LJ, Jenkins SM, Smith C, Katzmann JA, Snyder MR.

Am J Clin Pathol. 2012 Sep;138(3):398-405. doi: 10.1309/AJCPMEEJK32ACYFP.

PMID:
22912357
26.

Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition.

Therneau TM, Kyle RA, Melton LJ 3rd, Larson DR, Benson JT, Colby CL, Dispenzieri A, Kumar S, Katzmann JA, Cerhan JR, Rajkumar SV.

Mayo Clin Proc. 2012 Nov;87(11):1071-9. doi: 10.1016/j.mayocp.2012.06.014. Epub 2012 Aug 7.

27.

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.

Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton LJ 3rd, Benson JT, Colby CL, Dispenzieri A, Landgren O, Kumar S, Bradwell AR, Cerhan JR, Rajkumar SV.

Leukemia. 2013 Jan;27(1):208-12. doi: 10.1038/leu.2012.189. Epub 2012 Jul 11.

28.

Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population.

Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Therneau TM, Colby CL, Clark RJ, Mead GP, Kumar S, Melton LJ 3rd, Rajkumar SV.

Mayo Clin Proc. 2012 Jun;87(6):517-23. doi: 10.1016/j.mayocp.2012.03.009.

29.

Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma.

Greenberg AJ, Rajkumar SV, Larson DR, Dispenzieri A, Therneau TM, Colby CL, Phelps TK, Kumar SK, Katzmann JA, Kyle RA, Slager SL, Vachon CM.

Br J Haematol. 2012 May;157(4):472-5.

30.

Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms.

Pardanani A, Lasho TL, Finke CM, Rajkumar SV, Singh PP, Ketterling RP, Hanson CA, Katzmann JA, Tefferi A.

J Clin Oncol. 2012 Apr 1;30(10):1087-94. doi: 10.1200/JCO.2011.39.0310. Epub 2012 Feb 13.

PMID:
22331938
31.

A 71-year-old woman with multiple myeloma status after stem cell transplantation.

Donato LJ, Zeldenrust SR, Murray DL, Katzmann JA.

Clin Chem. 2011 Dec;57(12):1645-8. doi: 10.1373/clinchem.2011.163766. No abstract available.

32.

Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma.

Thompson CA, Maurer MJ, Cerhan JR, Katzmann JA, Ansell SM, Habermann TM, Macon WR, Weiner GJ, Link BK, Witzig TE.

Am J Hematol. 2011 Dec;86(12):998-1000. doi: 10.1002/ajh.22168. Epub 2011 Oct 17.

33.

Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies.

Katzmann JA, Snyder MR, Rajkumar SV, Kyle RA, Therneau TM, Benson JT, Dispenzieri A.

Clin Chem. 2011 Dec;57(12):1687-92. doi: 10.1373/clinchem.2011.171314. Epub 2011 Oct 6.

34.

Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia.

Maurer MJ, Cerhan JR, Katzmann JA, Link BK, Allmer C, Zent CS, Call TG, Rabe KG, Hanson CA, Kay NE, Slager SL, Witzig TE, Shanafelt TD.

Blood. 2011 Sep 8;118(10):2821-6. doi: 10.1182/blood-2011-04-349134. Epub 2011 Jul 15.

35.

High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, Africa.

Buadi F, Hsing AW, Katzmann JA, Pfeiffer RM, Waxman A, Yeboah ED, Biritwum RB, Tettey Y, Adjei A, Chu LW, DeMarzo A, Netto GJ, Dispenzieri A, Kyle RA, Rajkumar SV, Landgren O.

Am J Hematol. 2011 Jul;86(7):554-8. doi: 10.1002/ajh.22040. Epub 2011 Jun 14.

36.

Simultaneous phenotyping and quantification of α-1-antitrypsin by liquid chromatography-tandem mass spectrometry.

Chen Y, Snyder MR, Zhu Y, Tostrud LJ, Benson LM, Katzmann JA, Bergen HR 3rd.

Clin Chem. 2011 Aug;57(8):1161-8. doi: 10.1373/clinchem.2011.163006. Epub 2011 Jun 2.

37.

Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.

Maurer MJ, Micallef IN, Cerhan JR, Katzmann JA, Link BK, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Ansell SM, Porrata LF, Johnston PB, Nowakowski GS, Thompson CA, Gupta M, Syrbu SI, Kurtin PJ, Macon WR, Nikcevich DA, Witzig TE.

J Clin Oncol. 2011 Apr 20;29(12):1620-6. doi: 10.1200/JCO.2010.29.4413. Epub 2011 Mar 7.

38.

Alpha1-antitrypsin deficiency carriers, serum alpha 1-antitrypsin concentration, and non-small cell lung cancer survival.

Li Y, Krowka MJ, Qi Y, Katzmann JA, Song Y, Li Y, Mandrekar SJ, Yang P.

J Thorac Oncol. 2011 Feb;6(2):291-5. doi: 10.1097/JTO.0b013e31820213fb.

39.

Specificity of serum and urine protein electrophoresis for the diagnosis of monoclonal gammopathies.

Katzmann JA, Stankowski-Drengler TJ, Kyle RA, Karen SL, Snyder MR, Lust JA, Dispenzieri A.

Clin Chem. 2010 Dec;56(12):1899-900. doi: 10.1373/clinchem.2010.152280. Epub 2010 Sep 15. No abstract available.

40.

Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.

Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, Hayman SR, Buadi FK, Leung N, Zeldenrust SR, Ramirez-Alvarado M, Clark RJ, Kyle RA, Rajkumar SV, Gertz MA.

Blood. 2010 Dec 9;116(24):5126-9. doi: 10.1182/blood-2010-06-290668. Epub 2010 Aug 26.

41.

Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma.

Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann JA, Snyder M, Blood E, DeGoey R, Henderson K, Kyle RA, Bradwell AR, Greipp PR, Rajkumar SV, Fonseca R.

Leukemia. 2010 Aug;24(8):1498-505. doi: 10.1038/leu.2010.128. Epub 2010 Jun 3.

42.

Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome.

Stankowski-Drengler T, Gertz MA, Katzmann JA, Lacy MQ, Kumar S, Leung N, Hayman SR, Buadi F, Kyle RA, Rajkumar SV, Dispenzieri A.

Am J Hematol. 2010 Jun;85(6):431-4. doi: 10.1002/ajh.21707.

43.

Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.

Bianchi G, Kyle RA, Colby CL, Larson DR, Kumar S, Katzmann JA, Dispenzieri A, Therneau TM, Cerhan JR, Melton LJ 3rd, Rajkumar SV.

Blood. 2010 Sep 23;116(12):2019-25; quiz 2197. doi: 10.1182/blood-2010-04-277566. Epub 2010 May 21.

44.

Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, Colby CL, Therneau TM, Clark R, Kumar SK, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV.

Lancet. 2010 May 15;375(9727):1721-8. doi: 10.1016/S0140-6736(10)60482-5. Erratum in: Lancet. 2010 Jul 31;376(9738):332.

45.

Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women.

Landgren O, Rajkumar SV, Pfeiffer RM, Kyle RA, Katzmann JA, Dispenzieri A, Cai Q, Goldin LR, Caporaso NE, Fraumeni JF, Blot WJ, Signorello LB.

Blood. 2010 Aug 19;116(7):1056-9. doi: 10.1182/blood-2010-01-262394. Epub 2010 Apr 26.

46.

Circulating serum free light chains as predictive markers of AIDS-related lymphoma.

Landgren O, Goedert JJ, Rabkin CS, Wilson WH, Dunleavy K, Kyle RA, Katzmann JA, Rajkumar SV, Engels EA.

J Clin Oncol. 2010 Feb 10;28(5):773-9. doi: 10.1200/JCO.2009.25.1322. Epub 2010 Jan 4.

47.

Sharply increased serum free light-chain concentrations after treatment for multiple myeloma.

Murata K, Clark RJ, Lockington KS, Tostrud LJ, Greipp PR, Katzmann JA.

Clin Chem. 2010 Jan;56(1):16-8. doi: 10.1373/clinchem.2009.133041. No abstract available.

48.

IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis.

Zhang L, Lewis JT, Abraham SC, Smyrk TC, Leung S, Chari ST, Poterucha JJ, Rosen CB, Lohse CM, Katzmann JA, Wu TT.

Am J Surg Pathol. 2010 Jan;34(1):88-94. doi: 10.1097/PAS.0b013e3181c6c09a.

PMID:
20035148
49.

Screening panels for monoclonal gammopathies: time to change.

Katzmann JA.

Clin Biochem Rev. 2009 Aug;30(3):105-11.

50.

Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study.

Tsai HT, Caporaso NE, Kyle RA, Katzmann JA, Dispenzieri A, Hayes RB, Marti GE, Albitar M, Ghia P, Rajkumar SV, Landgren O.

Blood. 2009 Dec 3;114(24):4928-32. doi: 10.1182/blood-2009-08-237651. Epub 2009 Oct 14.

Supplemental Content

Loading ...
Support Center